ScinoPharm Taiwan, Ltd. (TPE: 1789)
Taiwan
· Delayed Price · Currency is TWD 24.70
+0.05 (0.20%)
Sep 13, 2024, 1:30 PM CST
ScinoPharm Taiwan Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 3,428 | 3,186 | 3,264 | 2,762 | 3,083 | 2,893 | Upgrade
|
| Revenue Growth (YoY) | 9.75% | -2.39% | 18.16% | -10.40% | 6.57% | -17.92% | Upgrade
|
| Cost of Revenue | 2,095 | 1,970 | 2,013 | 1,482 | 1,765 | 1,716 | Upgrade
|
| Gross Profit | 1,333 | 1,216 | 1,251 | 1,280 | 1,317 | 1,176 | Upgrade
|
| Selling, General & Admin | 557.33 | 543.83 | 573.88 | 685.79 | 696.32 | 670.96 | Upgrade
|
| Research & Development | 333.62 | 357.74 | 271.26 | 305.95 | 245.63 | 238.37 | Upgrade
|
| Operating Expenses | 891.17 | 901.5 | 845.28 | 991.87 | 941.74 | 909.55 | Upgrade
|
| Operating Income | 442.06 | 314.49 | 405.5 | 288.62 | 375.72 | 266.85 | Upgrade
|
| Interest Expense | -8.4 | -9.15 | -7.91 | -6.55 | -15.17 | -55.69 | Upgrade
|
| Interest & Investment Income | 57.18 | 53.63 | 22.12 | 19.38 | 27.41 | 37.98 | Upgrade
|
| Currency Exchange Gain (Loss) | 27.05 | -9.4 | 41.27 | -7.91 | -31.26 | 5.7 | Upgrade
|
| Other Non Operating Income (Expenses) | -21.8 | -0.31 | -22.88 | 7.63 | 0.68 | 10.96 | Upgrade
|
| EBT Excluding Unusual Items | 496.09 | 349.26 | 438.09 | 301.17 | 357.38 | 265.8 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.78 | -0.42 | -0.76 | -0.27 | -3.16 | -0.04 | Upgrade
|
| Asset Writedown | 0 | 0 | 0.63 | 1.38 | 4.28 | -0.71 | Upgrade
|
| Pretax Income | 495.31 | 348.84 | 437.96 | 302.29 | 358.51 | 265.05 | Upgrade
|
| Income Tax Expense | 92.31 | 61.78 | 84.74 | 58.82 | 76.44 | 48.4 | Upgrade
|
| Net Income | 403 | 287.06 | 353.22 | 243.47 | 282.07 | 216.66 | Upgrade
|
| Net Income to Common | 403 | 287.06 | 353.22 | 243.47 | 282.07 | 216.66 | Upgrade
|
| Net Income Growth | 54.35% | -18.73% | 45.08% | -13.68% | 30.19% | -51.09% | Upgrade
|
| Shares Outstanding (Basic) | 791 | 791 | 791 | 791 | 791 | 791 | Upgrade
|
| Shares Outstanding (Diluted) | 793 | 792 | 793 | 792 | 792 | 792 | Upgrade
|
| Shares Change (YoY) | 0.01% | -0.04% | 0.05% | 0.01% | 0.01% | -0.13% | Upgrade
|
| EPS (Basic) | 0.51 | 0.36 | 0.45 | 0.31 | 0.36 | 0.27 | Upgrade
|
| EPS (Diluted) | 0.50 | 0.36 | 0.45 | 0.31 | 0.36 | 0.27 | Upgrade
|
| EPS Growth | 51.40% | -19.41% | 45.08% | -13.68% | 32.12% | -51.79% | Upgrade
|
| Free Cash Flow | 339.92 | -37.3 | 530.51 | 195.4 | 766.34 | 686.43 | Upgrade
|
| Free Cash Flow Per Share | 0.43 | -0.05 | 0.67 | 0.25 | 0.97 | 0.87 | Upgrade
|
| Dividend Per Share | 0.300 | 0.300 | 0.360 | 0.480 | 0.500 | 0.270 | Upgrade
|
| Dividend Growth | -16.67% | -16.67% | -25.00% | -4.00% | 85.19% | -44.90% | Upgrade
|
| Gross Margin | 38.89% | 38.17% | 38.32% | 46.36% | 42.73% | 40.67% | Upgrade
|
| Operating Margin | 12.89% | 9.87% | 12.42% | 10.45% | 12.19% | 9.22% | Upgrade
|
| Profit Margin | 11.76% | 9.01% | 10.82% | 8.81% | 9.15% | 7.49% | Upgrade
|
| Free Cash Flow Margin | 9.92% | -1.17% | 16.25% | 7.07% | 24.86% | 23.73% | Upgrade
|
| EBITDA | 897.12 | 759.82 | 829.1 | 655.41 | 754.38 | 658.6 | Upgrade
|
| EBITDA Margin | 26.17% | 23.85% | 25.40% | 23.73% | 24.47% | 22.77% | Upgrade
|
| D&A For EBITDA | 455.06 | 445.33 | 423.61 | 366.79 | 378.66 | 391.74 | Upgrade
|
| EBIT | 442.06 | 314.49 | 405.5 | 288.62 | 375.72 | 266.85 | Upgrade
|
| EBIT Margin | 12.89% | 9.87% | 12.42% | 10.45% | 12.19% | 9.22% | Upgrade
|
| Effective Tax Rate | 18.64% | 17.71% | 19.35% | 19.46% | 21.32% | 18.26% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.